Blue Sky BioServices, founded in 2003 to serve the Boston area life sciences research hub, is the leading Contract Research Organization (CRO) providing R&D based Gene through Screen services for biotech and pharma companies from startups to established leaders in the field. Our customers enhance the quality and speed of their research by partnering with Blue Sky to receive world class services including; gene synthesis and bulk plasmid preparations, antibody cloning, scale-up production of recombinant proteins in multiple cell lines including mammalian, insect, bacterial and yeast, as well as antibody/protein purification and robust, rapid assay services such as cytotoxicity and qPCR, MSD. Our Assay team can support many commercially available screening technology in 96 and 384-well formats (fluorescent, colorimetric, etc.). Ultimately, we want to run YOUR assay, YOUR way. We will build out additional capabilities and capacity to support your screening workflow.
Blue Sky differentiates itself with its team of experienced scientists, leading edge process technology, and state-of-the-art laboratory facilities. Our commitment to scientific expertise and value has transformed the company into a center of excellence with unmatched quality and turnaround times.
We are motivated by ensuring our customers have an excellent experience working with Blue Sky. We do that by delivering projects on time, with high quality, at competitive prices, led by our team of highly skilled, energetic and collaborative scientists.
Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products’ development and manufacturing.
15,000 sq. m. Kemwell facility consists of a cGMP drug substance manufacturing area with over 4500L bioreactor capacity, sterile fill and finish areas for cGMP drug product manufacturing and process development laboratories to support production of protein therapeutics from mammalian-cell culture – monoclonal antibodies, bi-specific antibodies, fusion proteins, etc. Kemwell is capable of supporting novel, bio-better and biosimilar programs’ preclinical development, clinical development, cGMP clinical manufacturing and cGMP commercial manufacturing.
Kemwell, having established in 1980, had long term associations with pharma majors such as Bayer, GlaxoSmithKline, Merck KGaA, Novartis, Pfizer and others for small molecule contract mfg. and R&D. In 2016, Kemwell divested its small-molecule division to focus on biologics, leveraging its vast and rich experience. Kemwell is now a 100% biologics CDMO.
TGA BioServices, an Absorption Systems' Company, is an FDA inspected contract research laboratory providing the Pharmaceutical, Biotechnology and Research communities a comprehensive range of laboratory services in support of research and clinical studies. We offer the client a complete package of customized testing systems utilized in preclinical through Phase IV studies, all in compliance with cGLP and cGMP requirements.
We specialize in the development and validation of immunoassay systems for the detection of target molecules, antibody responses and quantification in total compliance with QA and cGMP standards.
TGA BioServices also offers in vivo mouse studies for the optimization of vaccine immunization schedules, dosing, adjuvant screening, immunogenicity testing for the release and stability of bulk and finished clinical product, as well as complete antibody development programs. Furthermore, we offer Guinea pig dermal sensitization testing for the identification of contact allergens. All programs are supervised by an in-house Institutional Animal Care and Use Committee (IACUC), while the facility is USDA registered and AAALAC accredited.
Other services provided include FACScan cell labeling studies, tissue culture, endotoxin testing, basic R&D activities, sample storage, specimen collection kits with on-site training, data management, protocol generation (SOP), database/statistical analysis and consultation. TGA BioServices has the credentials your project is searching for.
To create best niche antibody-based biologics for fulfilling the research and development needs in biomedical and biopharmaceutical communities. Our long range goal is to develop therapeutic and diagnostic entities.
ABB’s core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools.
Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABB’s scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG.
Massachusetts provides a vibrant and nurturing environment for life science ventures like ABB, in terms of training grants and tax benefits, as well as an abundant talent pool possessing a wide range of expertise. Discovering breakthrough biotechnology and exploring biologics for biomedical study is our mission at AB Biosciences. As part of our commitment to science education, we open our doors to intern students, who can experience firsthand the R&D employment possibilities in the Biotech Industry. More than 15 students/interns have visited our laboratory since 2009.
Founded in 2006, Abyntek Biopharma S.L. is a private Spanish company aimed at providing an integral and personalized service in the supply of antibodies.
Our company has two main business lines. On one hand, we are distributors of over twenty companies offering a comprehensive catalogue of more than 2 million antibodies, ELISA kits and proteins in general. On the other hand, we are the Spanish leading provider of custom monoclonal and polyclonal antibodies for R&D use. To this end, Abyntek can synthesize the necessary antigens (proteins and peptides) or make use of the client´s. We also offer antibody modifications such as biotinylation or conjugation to fluorophores and enzymes.
Come to visit our webpage (www.abyntek.com) and learn more about us. If you have any antibodies need, our international scientific team will be glad to help you!
Contact us and enjoy the experience of a special treat.